findmyKOL
Clinical trialNCT00002880CompletedPhase 2Interventional

Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

SponsorAlliance for Clinical Trials in OncologyEnrollment53Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Minnesota Cancer Center

    Minneapolis, Minnesota, United States

  • Washington University Barnard Cancer Center

    St Louis, Missouri, United States

  • St. Joseph'S Hospital and Medical Center

    Paterson, New Jersey, United States

  • Comprehensive Cancer Center of Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 1996
Primary completion
31 Jan 2001
Completion
31 Jan 2008
Last update posted
28 Jun 2016
Registered enrollment
53
Registry id
NCT00002880

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.